Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

NCT06504875 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: Tislelizumab
DRUG: Interleukin-2
DRUG: Capecitabine
DRUG: Oxaliplatin

Sponsor

The First Affiliated Hospital with Nanjing Medical University